- Company
- Exkivity, an exon 20-targeted anti-cancer drug, can be presc
- by Eo, Yun-Ho May 2, 2023 05:35am
- Exkivity, an anticancer drug targeting EGFR exon 20 insertion mutations, can be prescribed at general hospitals. According to related industries, Exkivity, a treatment for non-small cell lung cancer with an EGFR exon 20 insertion mutation of Takeda Pharmaceutical Korea, passed the Drug Committees of the National Cancer Center, Seoul National
- Company
- Gilead’s HCV drug occupies 19% of HCV market in 5 mths
- by Kim, Jin-Gu May 2, 2023 05:35am
- Gilead Science’s new hepatitis C treatment has made a successful soft landing in the market and derived good initial results. Epclusa and Vosevi, which were released in November last year, increased their market share to 19% in the oral hepatitis C treatment market in Q1 this year. On the other hand, the market share of Abbvie’s Mavyre
- Company
- SK Bioscience, Investing 2.4 trillion won over 5 years
- by Kim, Jin-Gu Apr 30, 2023 09:46am
- SK Bioscience has decided to invest 2.4 trillion won over the next five years. SK Bioscience announced on the 27th at 2:00 pm that it would announce its mid-to-long-term growth strategy to stock analysts and institutional investors. According to the disclosure, SK bioscience will spend 2.4 trillion won over the five years from this year to
- Company
- Hanmi, sales and operating profits highest in 8 years
- by Chon, Seung-Hyun Apr 28, 2023 05:49am
- Hanmi Pharmaceutical showed improved performance in the first quarter. Thanks to the high growth of new combination drugs such as Rosuzet and Amosartan family, both sales and operating profit recorded the highest level in eight years. Hanmi Pharmaceutical announced on the 26th that its operating profit in the first quarter was 60.5 billion won,
- Company
- Dupixent attempts to expand its reimb to infants in KOR
- by Eo, Yun-Ho Apr 28, 2023 05:49am
- Dupixent is attempting to expand insurance reimbursement to infants after succeeding to reimburse the drug to children. Dailpharm’s coverage showed that Sanofi-Aventis Korea recently submitted an application for an extension of reimbursement for infants aged 6 months to 5 years of age for its atopic dermatitis treatment Dupixent (dupil
- Policy
- Dual punishment for CSO rebate excluded from review
- by Lee, Jeong-Hwan Apr 28, 2023 05:49am
- An amendment to the Medical Service Act that applies a dual punishment system when doctors receive rebates paid by pharmaceutical contract sales organizations (CSOs) and an amendment to the Pharmaceutical Affairs Act to prohibit potential hospital/pharmacy owners and brokers from exchanging illegal hospital subsidies in exchange for prescr
- Company
- Antidiabetic Tenelia market rises 67% with entry of generics
- by Kim, Jin-Gu Apr 27, 2023 05:43am
- The teneligliptin antidiabetic market has expanded 1.7 times in a single year. This is analyzed to be influenced by the large amount of generics that entered the market in October last year. Only 5 months after its launch, prescriptions of Tenelia generics that were launched exceeded KRW 10 billion, and their market share grew to 41%. s
- Company
- Need strong cost control for biopharmaceuticals in 2nd half
- by Jung, Sae-Im Apr 27, 2023 05:43am
- It was predicted that the pharmaceutical and bio sectors would continue their unstable trend in the second half. It has emerged as the biggest challenge for small and medium-sized enterprises (SMEs) to withstand the harsh cold weather of the financial crisis through strong cost control. In the second half of the year, if interest rates peak
- Company
- Yuhan’s Q1 operating profit rose fourfold this year
- by Chon, Seung-Hyun Apr 27, 2023 05:43am
- Yuhan Corp showed improved performance in Q1 compared to the previous year. A large amount of revenue from contract development and manufacturing (CDMO) royalties flowed in from its subsidiary Ad Pharma. Yuhan Corp announced on the 26th that operating profit based on its consolidated financial statements in Q1 was KRW 22.6 billion, which is a
- Company
- GSK, cash equivalents of 250,000 won
- by Jung, Sae-Im Apr 27, 2023 05:41am
- GSK Korea's cash flow is rapidly deteriorating. It has not been able to generate cash through operating activities for three consecutive years, so money is not circulating. Cash equivalents fell to 250,000 won. Short-term borrowings borrowed to raise operating funds exceeded 90 billion won. According to the Financial Supervisory Service on th
